DAPK1 and non-small cell lung carcinoma: Furthermore, we suggest that DANGER and DAPK could be attractive pharmaceutical targets for overcoming HG-induced radioresistance of NSCLC and ultimately contribute to the effective treatment of lung cancer with radiation.